Claims for Patent: 7,871,622
✉ Email this page to a colleague
Summary for Patent: 7,871,622
Title: | Stably tethered structures of defined compositions with multiple functions or binding specificities |
Abstract: | The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. The disclosed methods and compositions provide a simple, easy to purify way to obtain any binary compound attached to any monomeric compound, or any trinary compound. |
Inventor(s): | Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Woodland Park, NJ) |
Assignee: | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) |
Application Number: | 12/396,965 |
Patent Claims: | 1. A method of delivering a diagnostic or therapeutic agent comprising: a) obtaining a stably tethered structure that has (i) two copies of a first monomer comprising a DDD moiety
attached to a first antigen binding fragment, wherein the DDD moiety consists the peptide sequence of SEQ ID NO: 1 (DDD1) or SEQ ID NO: 2 (DDD2) from a dimerization and docking domain of human protein kinase A RII.alpha.; and (ii) one copy of a second
monomer comprising an AD moiety attached to a second antigen binding fragment, wherein the AD moiety consists the peptide sequence of SEQ ID NO: 3 (AD1) or SEQ ID NO: 4 (AD2) from an anchoring domain of an AKAP (A-kinase anchoring protein), wherein the
two DDD moieties bind to the AD moiety to form a stably tethered structure and wherein the stably tethered structure has at least one binding site for a targetable construct selected from the group consisting of Histidine-Serine-Glycine (HSG) and
Indium-DTPA (In-DPTA); b) administering the stably tethered structure to a subject; and c) administering to the subject a targetable construct HSG or In-DPTA that comprises at least one diagnostic or therapeutic agent.
2. The method of claim 1, wherein the first and second monomers are fusion proteins. 3. The method of claim 2, wherein the first and second antigen binding fragments are selected from the group consisting of a Fab antibody fragment, a Fab' antibody fragment, an scFv antibody fragment, a diabody and a single domain antibody (DAB). 4. The method of claim 3, wherein the first or second antigen binding fragment has a binding affinity for a tumor-associated antigen. 5. The method of claim 4, wherein the tumor-associated antigen is selected from the group consisting of carbonic anhydrase IX, alpha-fetoprotein, CA125, CD1, CD1a, CD3, CD5, CD15, CD16, CD19, CD20, CD21, CD22, CD23, CD25, CD30, CD33, CD38, CD45, CD74, CD79a, CD80, CD138, colon-specific antigen-p (CSAp), CEA (CEACAM5), CEACAM6, EGFR, EGP-1, EGP-2, Ep-CAM, Flt-1, Flt-3, folate receptor, G250 antigen, HLA-DR, human chorionic gonadotropin (HCG) and its subunits thereof, HER2/neu, hypoxia inducible factor (HIF-1), Ia, IL-2, IL-6, IL-8, insulin growth factor-1 (IGF-1), KC4-antigen, KS-1-antigen, KS1-4, Le-Y, macrophage migration inhibitory factor (MIF), MAGE, MUC1, MUC2, MUC3, MUC4, NCA66, NCA95, NCA90, placental growth factor, p53, prostatic acid phosphatase, PSA, PSMA, RS5, S100, TAC, TAG-72, tenascin, TRAIL receptors, Thomson-Friedenreich antigens, tumor necrosis antigens, VEGF, ED-B fibronectin; and 17-1A-antigen. 6. The method of claim 1, wherein the therapeutic agent is a chemotherapeutic agent, a cytokine, a chemokine, an anti-angiogenic agent, an apoptotic agent, a drug, a prodrug, a toxin, an enzyme, a radioisotope, an immunomodulator, an antibiotic or a hormone. 7. The method of claim 1, wherein the antigen binding is selected from the group consisting of LL1 (anti-CD74), LL2 (anti-CD22), RFB4 (anti-CD22), A20 (anti-CD20), L243 (anti-HLA class II), CC49 (anti-TAG-72), MN-14 (anti-CEA), MN-15 (anti-CEA), 679 (anti-HSG), 734 (anti-In-DTPA), L19 (anti-ED-B fibronectin), R1 (anti-IGF-1R), PAM4 (anti-MUC 1), RS7 (anti-EGP-1), adalimumab, infliximab, omalizumab and palivizumab. 8. The method of claim 3, wherein the antigen binding fragments are human, humanized or chimeric antibody fragments. 9. The method of claim 1, wherein the diagnostic agent is selected from the group consisting of a radioisotope, an imaging agent, a dye, an enzyme, a fluorescent agent, a chemiluminescent agent, a bioluminescent agent, a paramagnetic ion and an ultrasound label. 10. The method of claim 1, wherein the subject has cancer or autoimmune disease. 11. The method of claim 1, wherein the disease or condition is cancer and the stably tethered structure comprises at least one antigen-binding antibody fragment thereof with a binding affinity for a tumor-associated antigen selected from the group consisting of carbonic anhydrase IX, alpha-fetoprotein, CA125, CD1, CD1a, CD3, CD5, CD15, CD16, CD19, CD20, CD21, CD22, CD23, CD25, CD30, CD33, CD38, CD45, CD74, CD79a, CD80, CD138, colon-specific antigen-p (CSAp), CEA (CEACAM5), CEACAM6, EGFR, EGP-1, EGP-2, Ep-CAM, Flt-1, Flt-3, folate receptor, G250 antigen, HLA-DR, human chorionic gonadotropin (HCG) and its subunits, HER2/neu, hypoxia inducible factor (HIF-1), Ia, IL-2, IL-6, IL-8, insulin growth factor-1 (IGF-1), KC4-antigen, KS-1-antigen, KS1-4, Le-Y, macrophage migration inhibitory factor (MIF), MAGE, MUC1, MUC2, MUC3, MUC4, NCA66, NCA95, NCA90, placental growth factor, p53, prostatic acid phosphatase, PSA, PSMA, RS5, S100, TAC, TAG-72, tenascin, TRAIL receptors, Thomson-Friedenreich antigens, tumor necrosis antigens, VEGF, ED-B fibronectin and 17-1A-antigen. 12. The method of claim 10, further comprising administering one or more anti-cancer therapies in combination with the stably tethered structure. 13. The method of claim 12, wherein the therapy comprises administering a chemotherapeutic agent, a cytokine, radiation therapy, immunotherapy, radioimmunotherapy, localized hyperthermia, laser irradiation, an anti-angiogenic agent or surgical excision. 14. The method of claim 10, wherein the cancer is selected from the group consisting of epithelial cancer, mesenchymal cancer, hematological cancer, neural cancer, carcinoma, melanoma, sarcoma, neuroblastoma, leukemia, lymphoma, glioma and myeloma. |
Details for Patent 7,871,622
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 01/15/1974 | ⤷ Try a Trial | 2025-04-06 |
Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 12/27/1984 | ⤷ Try a Trial | 2025-04-06 |
Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 02/15/1985 | ⤷ Try a Trial | 2025-04-06 |
Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 02/16/1990 | ⤷ Try a Trial | 2025-04-06 |
Bel-mar Laboratories, Inc. | CHORIONIC GONADOTROPIN | chorionic gonadotropin | Injection | 017054 | 03/26/1974 | ⤷ Try a Trial | 2025-04-06 |
Fresenius Kabi Usa, Llc | CHORIONIC GONADOTROPIN | chorionic gonadotropin | For Injection | 017067 | 03/05/1973 | ⤷ Try a Trial | 2025-04-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.